Literature DB >> 17079777

Diversity of the angiogenic phenotype in non-small cell lung cancer.

Marc R McClelland1, Shannon L Carskadon, Liujian Zhao, Eric S White, David G Beer, Mark B Orringer, Allan Pickens, Andrew C Chang, Douglas A Arenberg.   

Abstract

Angiogenesis is crucial for tumor biology. There are many mechanisms by which tumors induce angiogenesis. We hypothesize that each individual tumor develops a unique mechanism to induce angiogenesis, and that activation of a particular angiogenic pathway suppresses the evolution of alternative pathways. We characterized 168 human non-small cell lung cancer (NSCLC) specimens for levels of angiogenic factors (angiogenic CXC chemokines, basic fibroblast growth factor, and vascular endothelial growth factor). We also induced lung tumor formation in A/J mice by injecting the tobacco carcinogen NNK. We dissected individual lung tumors and measured expression of angiogenic factors from three distinct families using real-time PCR. Finally, we controlled the angiogenic milieu using in vivo models to determine the resultant phenotype of the angiogenic factors expressed by NSCLC cells. Human tumors displayed marked variation in the expression of angiogenic factors. Individual mouse tumors, even from within the same mouse, displayed variability in their pattern of expression of angiogenic factors. In a sponge model of angiogenesis using murine lung cancer cells, implanting LLC cells with an angiogenic factor suppressed the expression of other angiogenic factors in implanted sponges. This suppressive effect was not seen in vitro. We conclude that lung cancer tumors evolve a unique and dominant angiogenic phenotype. Once an angiogenic pathway is activated, it may allow for tumor growth to proceed in the absence of a selection pressure to activate a second pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079777      PMCID: PMC1899317          DOI: 10.1165/rcmb.2006-0311OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  36 in total

Review 1.  Intratumor microvessel density as a prognostic factor in cancer.

Authors:  N Weidner
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

2.  The functional role of the ELR motif in CXC chemokine-mediated angiogenesis.

Authors:  R M Strieter; P J Polverini; S L Kunkel; D A Arenberg; M D Burdick; J Kasper; J Dzuiba; J Van Damme; A Walz; D Marriott
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

3.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.

Authors:  D A Arenberg; S L Kunkel; P J Polverini; M Glass; M D Burdick; R M Strieter
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.

Authors:  J A Forsythe; B H Jiang; N V Iyer; F Agani; S W Leung; R D Koos; G L Semenza
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

6.  Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction.

Authors:  C Marshall; A J Mamary; A J Verhoeven; B E Marshall
Journal:  Am J Respir Cell Mol Biol       Date:  1996-11       Impact factor: 6.914

Review 7.  The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.

Authors:  D A Arenberg; P J Polverini; S L Kunkel; A Shanafelt; J Hesselgesser; R Horuk; R M Strieter
Journal:  J Leukoc Biol       Date:  1997-11       Impact factor: 4.962

8.  Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.

Authors:  D Brattström; M Bergqvist; A Larsson; J Holmertz; P Hesselius; L Rosenberg; O Brodin; G Wagenius
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

9.  Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.

Authors:  D A Arenberg; S L Kunkel; P J Polverini; S B Morris; M D Burdick; M C Glass; D T Taub; M D Iannettoni; R I Whyte; R M Strieter
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.

Authors:  M I Koukourakis; A Giatromanolaki; S Kakolyris; K J O'Byrne; N Apostolikas; J Skarlatos; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more
  9 in total

Review 1.  Update in lung cancer 2007.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2008-05-01       Impact factor: 21.405

2.  CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes.

Authors:  Oksana Kowalczuk; Tomasz Burzykowski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Lech Chyczewski; Jacek Niklinski
Journal:  Tumour Biol       Date:  2014-02-06

3.  Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.

Authors:  Aihua Li; Jonathan King; Aune Moro; Mark D Sugi; David W Dawson; Jeffrey Kaplan; Gang Li; Xuyang Lu; Robert M Strieter; Marie Burdick; Vay Liang W Go; Howard A Reber; Guido Eibl; O Joe Hines
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

4.  Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.

Authors:  Douglas Arenberg; Tracy R Luckhardt; Shannon Carskadon; Liujian Zhao; Mohammad A Amin; Alisa E Koch
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

5.  Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.

Authors:  Sultan Alhayyani; Louise McLeod; Alison C West; Jesse J Balic; Christopher Hodges; Liang Yu; Julian A Smith; Zdenka Prodanovic; Steven Bozinovski; Beena Kumar; Saleela M Ruwanpura; Mohamed I Saad; Brendan J Jenkins
Journal:  Oncogene       Date:  2021-12-03       Impact factor: 9.867

6.  Lung cancer with gastrointestinal metastasis - review of theories of metastasis with three rare case descriptions.

Authors:  Rohtesh S Mehta; Andrew D Liman; Vida A Passero; Agnes K Liman
Journal:  Cancer Microenviron       Date:  2013-08-21

7.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

Review 8.  Molecular Insights into Potential Contributions of Natural Polyphenols to Lung Cancer Treatment.

Authors:  Qingyu Zhou; Hua Pan; Jing Li
Journal:  Cancers (Basel)       Date:  2019-10-15       Impact factor: 6.639

9.  Hypoxia promotes the migration and invasion of human hepatocarcinoma cells through the HIF-1α-IL-8-Akt axis.

Authors:  Maoyun Fei; Jianming Guan; Tao Xue; Lianjin Qin; Chengwu Tang; Ge Cui; Yao Wang; Hui Gong; Wenming Feng
Journal:  Cell Mol Biol Lett       Date:  2018-09-20       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.